Date: 2012-11-12
Type of information: R&D agreement
Compound: therapeutic approach to an undisclosed indication using ActoBiotics™
Company: ActoGeniX (Belgium) Merck&Co (USA)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism: ActoBiotics™ represent a novel concept for oral administration of therapeutic proteins. ActoBiotics™ can deliver a wide range of therapeutic peptides and proteins, including monoclonal antibodies, antibody fragments, cytokines, antigens, and hormones.
Disease: undisclosed
Details: * On November 12, 2012, ActoGeniX, a clinical stage biopharmaceutical company, has announced the signing of a research collaboration agreement with Merck&Co, to develop and validate a therapeutic approach to an undisclosed indication using ActoBiotics™, a novel class of orally administered and locally acting biopharmaceuticals. This approach is based on the oral administration and local enteric delivery of antibodies, which are expressed and secreted at the enteric mucosa by the ActoBiotics™ technology.
Financial terms:
Latest news:
